FDA is moving to establish comparative effectiveness standards for approval of new opioids, according to draft guidance issued Thursday on conducting benefit-risk assessments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,